国产坎地沙坦酯片治疗轻中度原发性高血压的疗效和安全性  

Clinical Efficacy and Safety of Candesartan Cilexetil in Patients with Mild-to-Moderate Essential Hypertension

作　　者：黄高忠[1] 王丽娟[1] 吴宗贵[1] 顾兴建[1] 杜荣增[1] 张亚文[1] 

机构地区：[1]上海第二军医大学长征医院心内科,上海200003

出　　处：《高血压杂志》2004年第5期404-407,共4页Chinese Journal of Hypertension

摘　　要：目的　评价坎地沙坦酯片治疗轻中度原发性高血压的疗效和安全性。方法　随机、双盲、双模拟、阳性药物 (氯沙坦 )平行对照。 6 1例轻、中度原发性高血压服用坎地沙坦酯片或氯沙坦片各 1片 ,1次 /d ,必要时增加剂量 1次。总疗程 8周。结果　氯沙坦组治疗前的血压为 (14 6 .2±11.6 ) / (10 0 3± 3.3)mmHg,治疗后的血压为 (130 3± 9.8) / (85 .7± 8 0 )mmHg,血压下降幅度为(16 0± 11.8) / (14 .6± 6 .8)mmHg;坎地沙坦酯组治疗前的血压为 (14 3.4± 11.2 ) / (10 0 6± 4 .1)mmHg,治疗后的血压为 (130 4± 11.2 ) / (86 .3± 8 0 )mmHg,血压下降幅度为 (13 0± 8.7) / (14 .3±6 .5 )mmHg。两组治疗后血压降低幅度均有统计学意义 ,主要降幅均在前 2周。组间无差异。治疗前后心率无明显变化。坎地沙坦酯和氯沙坦降压显效率分别为 6 0 7%和 6 0 0 % ,总有效率分别为82 .1%和 76 .7% ,组间无差别。不良事件坎地沙坦酯和氯沙坦组为头晕各 2例和 1例 ,血生化等实验室指标无异常改变。结论　国产坎地沙坦酯片治疗轻中度原发性高血压不良反应发生率很低 ,本文无 1例出现咳嗽 ,耐受性良好 ,适用于长期治疗。Objective To evaluate the efficacy and safety of domest ic produced candesartan cilexetil in patients with mild-to-moderate essential hypertension. Methods Sixty one patients were randomLy assigned to receive candesartan cilexetil (8 mg/d) or losartan (50 mg/d) . The dosages wer e titrated to double the doses when DBP was sustained≥90 \{mm Hg\} or the magni tude of reduction was less than 10 \{mm Hg\}. Results Systolic bloo d pressure (SBP)/diastolic blood pressure (DBP) decreased significantly from (14 6.2±11.6)/(1003±3.3)\{mm Hg\} to (1303±9.8)/(85.7±80)\{mm Hg\} in losartan group and from (143.4±11.2)/(1006±4.1)\{mm Hg\} to (1304 ±11.2)/(86.3±80)\{mm Hg\} in candesartan group. The responsive rate was 82.1% in candesartan group, and 76.7% in losartan group. No change in heart ra te was found. Adverse reactions were slight. Conclusion Domestic produced candesartan cilexetil was proved to be a stable and efficacious antihyp ertensive medication with little adverse reactions. It appears as effective and safe as losartan and appears to be suitable for long term treatment of essentia l hypertension.

关 键 词：国产坎地沙坦酯片 治疗 原发性高血压 安全性 疗效观察 

分 类 号：R544.1[医药卫生—心血管疾病]